Loading...
Loading...
NEW YORK, NY · CIK 0001263508
Portfolio Value
$12.02B
Positions
134
New
21
Increased
23
Decreased
60
Sold Out
10
BAKER BROS. ADVISORS LP (NEW YORK, NY) reported a portfolio value of $12.02B across 134 positions in their Q1 2015 SEC 13F filing (period ending 2015-03-31). The top 10 positions account for 76.7% of the portfolio.
Top 30 holdings by portfolio weight. Block width = holding percentage. Green = new/increased, red = reduced, gray = unchanged.
| # | Stock | Value↓ | Weight | Change |
|---|---|---|---|---|
| 1 | Pharmacyclics Inc. | $2.31B | 19.24% | -1.0% |
| 2 | INCYIncyte Corp. | $1.36B | 11.32% | - |
| 3 | Synageva Biopharma Corp. | $1.14B | 9.46% | +9.4% |
| 4 | SGENEURSeattle Genetics, Inc. | $1.02B | 8.49% | +3.6% |
| 5 | SLXP 2.75 05/15/15Salix Pharmaceuticals Inc. 2.75% 5/15/15 | $801.15M | 6.66% | -1.5% |
| 6 | ACADAcadia Pharmaceuticals Inc. | $667.49M | 5.55% | - |
| 7 | BMRNBiomarin Pharmaceuticals Inc. | $523.46M | 4.35% | +13.1% |
| 8 | Incyte Corp. Notes 1.25% 11/15/2020 144A | $508.43M | 4.23% | - |
| 9 | Incyte Corp. Notes 0.375% 11/15/2018 144A | $471.94M | 3.93% | - |
| 10 | INCY 4.75 10/01/15Incyte Corp. Notes 4.75% 10/1/2015 144A | $421.67M | 3.51% | - |
| Stock | Value | Shares |
|---|---|---|
| NVTA1EURInvitae Corp. | $109.86M | 6,554,967 |
| ONCEEURSpark Therapeutics, Inc. | $102.88M | 1,327,451 |
| Lion Biotechnologies Inc. | $16.05M | 1,325,000 |
| IMGNEURImmunogen, Inc. | $8.95M | 999,496 |
| TTH1EURTransition Therapeutics, Inc. | $5.25M | 769,230 |
| Amarin Corp. PLC | $5.16M | 2,205,710 |
| ARRY 3 06/01/20Array Biopharma, Inc. Notes 3.0% 6/1/2020 | $3.76M | 3,000,000 |
| FGOZafgen, Inc. | $3.75M | 94,745 |
| ZFGNUSDZafgen, Inc. | $3.75M | 94,745 |
| Assembly Biosciences, Inc. | $3.31M | 250,000 |
Get alerts when BAKER BROS. ADVISORS LP files new 13F holdings.